Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization
dc.contributor.author | Jiang, Wenxia | |
dc.contributor.author | Maldeney, Alexander R. | |
dc.contributor.author | Yuan, Xue | |
dc.contributor.author | Richer, Martin J. | |
dc.contributor.author | Renshaw, Scott E. | |
dc.contributor.author | Luo, Wei | |
dc.contributor.department | Microbiology and Immunology, School of Medicine | |
dc.date.accessioned | 2024-06-11T17:23:44Z | |
dc.date.available | 2024-06-11T17:23:44Z | |
dc.date.issued | 2024 | |
dc.description.abstract | mRNA vaccines have proven to be pivotal in the fight against COVID-19. A recommended booster, given 3 to 4 weeks post the initial vaccination, can substantially amplify protective antibody levels. Here, we show that, compared to contralateral boost, ipsilateral boost of the SARS-CoV-2 mRNA vaccine induces more germinal center B cells (GCBCs) specific to the receptor binding domain (RBD) and generates more bone marrow plasma cells. Ipsilateral boost can more rapidly generate high-affinity RBD-specific antibodies with improved cross-reactivity to the Omicron variant. Mechanistically, the ipsilateral boost promotes the positive selection and plasma cell differentiation of pre-existing GCBCs from the prior vaccination, associated with the expansion of T follicular helper cells. Furthermore, we show that ipsilateral immunization with an unrelated antigen after a prior mRNA vaccination enhances the germinal center and antibody responses to the new antigen compared to contralateral immunization. These findings propose feasible approaches to optimize vaccine effectiveness. | |
dc.eprint.version | Author's manuscript | |
dc.identifier.citation | Jiang W, Maldeney AR, Yuan X, Richer MJ, Renshaw SE, Luo W. Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization. Cell Rep. 2024;43(1):113665. doi:10.1016/j.celrep.2023.113665 | |
dc.identifier.uri | https://hdl.handle.net/1805/41429 | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | |
dc.relation.isversionof | 10.1016/j.celrep.2023.113665 | |
dc.relation.journal | Cell Reports | |
dc.rights | Publisher Policy | |
dc.source | PMC | |
dc.subject | Immunology | |
dc.subject | Antibody | |
dc.subject | Germinal center | |
dc.subject | mRNA vaccine | |
dc.subject | Plasma cell | |
dc.title | Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization | |
dc.type | Article |